, Volume 64, Issue 6, pp 630–630 | Cite as

Is Omapatrilat a Novel Therapy of the Past Rather Than the Future?

  • Tsung O. Cheng


Cardiol Enalapril Endopeptidase Cardiovascular Disorder Death Sentence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 2003; 63(20): 2185–202PubMedCrossRefGoogle Scholar
  2. 2.
    Cheng TO. Omapatrilat May Indeed NOt be mUch Superior (OMINOUS) [letter]. Int J Cardiol 2003; 91: 113PubMedCrossRefGoogle Scholar
  3. 3.
    Coats AJ. Omapatrilat: the story of Overture and Octave. Int J Cardiol 2002; 86: 1–4PubMedCrossRefGoogle Scholar
  4. 4.
    Cheng TO, Julian D. Acronyms of cardiologic trials: 2002. Int J Cardiol 2003; 91: 261–351PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Tsung O. Cheng
    • 1
  1. 1.George Washington University Medical CenterWashingtonUSA

Personalised recommendations